A decade of modeling Alzheimer's disease in transgenic mice

Trends in Genetics

Volumn 22, Issue 5, 2006, Pages 281-289

  McGowan, Eileen ^a   Eriksen, Jason ^a   Hutton, Michael ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PROTEIN; OLIGOMER;

ALZHEIMER DISEASE; AMNESIA; DISEASE COURSE; GENE EXPRESSION; HUMAN; IMMUNOREACTIVITY; IMMUNOTHERAPY; LONG TERM POTENTIATION; MOUSE; MUTATION; NERVE CELL NECROSIS; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STATISTICAL SIGNIFICANCE; TRANSGENE; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, TRANSGENIC; TAU PROTEINS;

MUS MUSCULUS;

EID: 33646126924     PISSN: 01689525     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tig.2006.03.007     Document Type: Review

References (79)

1. Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron 6 (1991) 487-498
2. Games D., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373 (1995) 523-527
3. Hsiao K., et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274 (1996) 99-102
4. Chishti M.A., et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 276 (2001) 21562-21570
5. Janus C., et al. New developments in animal models of Alzheimer's disease. Curr. Neurol. Neurosci. Rep. 1 (2001) 451-457
6. Mucke L., et al. High-level neuronal expression of Aβ 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20 (2000) 4050-4058
7. Duff K., et al. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1. Nature 383 (1996) 710-713
8. Borchelt D.R., et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19 (1997) 939-945
9. Holcomb L., et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4 (1998) 97-100
10. Borchelt D.R., et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo. Neuron 17 (1996) 1005-1013
11. Citron M., et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat. Med. 3 (1997) 67-72
12. Irizarry M.C., et al. APPSw transgenic mice develop age-related Aβ deposits and neuropil abnormalities, but no neuronal loss in CA1. J. Neuropathol. Exp. Neurol. 56 (1997) 965-973
13. Frautschy S.A., et al. Microglial response to amyloid plaques in APPsw transgenic mice. Am. J. Pathol. 152 (1998) 307-317
14. Irizarry M.C., et al. Aβ deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J. Neurosci. 17 (1997) 7053-7059
15. Fryer J.D., et al. Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice. J. Neurosci. 23 (2003) 7889-7896
16. McGowan E., et al. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47 (2005) 191-199
17. Miao J., et al. Cerebral microvascular amyloid β protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid β precursor protein. Am. J. Pathol. 167 (2005) 505-515
18. Herzig M.C., et al. Aβ is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat. Neurosci. 7 (2004) 954-960
19. Davis J., et al. Early-onset and robust cerebral microvascular accumulation of amyloid β-protein in transgenic mice expressing low levels of a vasculotropic dutch/iowa mutant form of amyloid β-protein precursor. J. Biol. Chem. 279 (2004) 20296-20306
20. Davis, J. et al. Deficient cerebral clearance of vasculotropic mutant Dutch/Iowa Double Aβ in human AβPP transgenic mice. Neurobiol. Aging (in press)
21. Vidal R., et al. A stop-codon mutation in the BRI gene associated with familial British dementia. Nature 399 (1999) 776-781
22. Vidal R., et al. A decamer duplication in the 3′ region of the BRI gene originates an amyloid peptide that is associated with dementia in a Danish kindred. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 4920-4925
23. Holtzman D.M., et al. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann. Neurol. 47 (2000) 739-747
24. Fryer J.D., et al. Human apolipoprotein e4 alters the Aβ 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J. Neurosci. 25 (2005) 2803-2810
25. Bales K.R., et al. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 15233-15238
26. Bales K.R., et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 17 (1997) 263-264
27. Westerman M.A., et al. The relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 22 (2002) 1858-1867
28. Chen G., et al. A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease. Nature 408 (2000) 975-979
29. Janus C., et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408 (2000) 979-982
30. Morgan D., et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 (2000) 982-985
31. +PS1 mice. Neurobiol. Aging 22 (2001) 377-385
32. Kotilinek L.A., et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 22 (2002) 6331-6335
33. Dodart J.C., et al. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat. Neurosci. 5 (2002) 452-457
34. Lambert M.P., et al. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 6448-6453
35. Walsh D.M., et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-539
36. Cleary J.P., et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 8 (2005) 79-84
37. Lesné, S. et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature (in press)
38. Takeuchi A., et al. Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss. Am. J. Pathol. 157 (2000) 331-339
39. Sturchler-Pierrat C., et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 13287-13292
40. Calhoun M.E., et al. Neuron loss in APP transgenic mice. Nature 395 (1998) 755-756
41. Calhoun M.E., et al. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 14088-14093
42. Urbanc B., et al. Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 13990-13995
43. Calon F., et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 43 (2004) 633-645
44. Spires T.L., et al. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J. Neurosci. 25 (2005) 7278-7287
45. Stern E.A., et al. Cortical synaptic integration in vivo is disrupted by amyloid-beta plaques. J. Neurosci. 24 (2004) 4535-4540
46. Tsai J., et al. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat. Neurosci. 7 (2004) 1181-1183
47. Lombardo J.A., et al. Amyloid-β antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J. Neurosci. 23 (2003) 10879-10883
48. Hsia A.Y., et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 3228-3233
49. Buttini M., et al. β-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J. Neurosci. 25 (2005) 9096-9101
50. Santa-Cruz K., et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309 (2005) 476-481
51. Allen B., et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J. Neurosci. 22 (2002) 9340-9351
52. Lewis J., et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25 (2000) 402-405
53. Zhang B., et al. Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy. J. Neurosci. 24 (2004) 4657-4667
54. Andorfer C., et al. Cell-cycle re-entry and cell death in transgenic mice expressing nonmutant human tau Isoforms. J. Neurosci. 25 (2005) 5446-5454
55. Ramsden M., et al. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J. Neurosci. 25 (2005) 10637-10647
56. Hutton M., et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393 (1998) 702-705
57. Poorkaj P., et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 43 (1998) 815-825
58. Braak H., and Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl.) 82 (1991) 239-259
59. Zehr C., et al. Apoptosis in oligodendrocytes is associated with axonal degeneration in P301L tau mice. Neurobiol. Dis. 15 (2004) 553-562
60. Migheli A., et al. A study of apoptosis in normal and pathologic nervous tissue after in situ end-labeling of DNA strand breaks. J. Neuropathol. Exp. Neurol. 53 (1994) 606-616
61. Ferrer I., et al. Phosphorylated map kinase (ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Brain Pathol. 11 (2001) 144-158
62. Zhang B., et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 227-231
63. Lewis J., et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293 (2001) 1487-1491
64. Ribe E.M., et al. Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice. Neurobiol. Dis. 20 (2005) 814-822
65. Perez M., et al. Characterization of a double (amyloid precursor protein-tau) transgenic: tau phosphorylation and aggregation. Neuroscience 130 (2005) 339-347
66. Gotz J., et al. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Aβ 42 fibrils. Science 293 (2001) 1491-1495
67. Masliah E., et al. β-amyloid peptides enhance β-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 12245-12250
68. Oddo S., et al. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol. Aging 24 (2003) 1063-1070
69. Billings L.M., et al. Intraneuronal Aβ causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45 (2005) 675-688
70. Oddo S., et al. Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43 (2004) 321-332
71. Oddo S., et al. Temporal profile of Aβ oligomerization in an in vivo model of Alzheimer's disease: a link between Aβ and tau pathology. J. Biol. Chem. 281 (2005) 1599-1604
72. Cruz J.C., et al. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40 (2003) 471-483
73. Hutton M. Missense and splice site mutations in tau associated with FTDP-17: multiple pathogenic mechanisms. Neurology 56 (2001) 21-25
74. Rovelet-Lecrux A., et al. APP locus duplication causes autosomal dominant early-onset alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 38 (2006) 24-26
75. Tanemura K., et al. Formation of filamentous tau aggregations in transgenic mice expressing V337M human tau. Neurobiol. Dis. 8 (2001) 1036-1045
76. Tatebayashi Y., et al. Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 13896-13901
77. Ramsden M., et al. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J. Neurosci. 25 (2005) 10637-10647
78. Andorfer C., et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem. 86 (2003) 582-590
79. Oddo S., et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron 39 (2003) 409-421